Safety of cemiplimab for advanced cutaneous squamous cell carcinoma in a patient with <scp>p‐ANCA</scp> ‐associated vasculitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of cemiplimab for advanced cutaneous squamous cell carcinoma in a patient with p‐ANCA ‐associated vasculitis

Published:2022-10-21 Issue:3 Volume:37 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Pham James P.¹²^ORCID,Sivasubramaniam Vanathi²³,Gallagher Richard¹²,Forstner Dion¹²⁴,Wong Muh⁵⁶,Liu Jia¹²⁶^ORCID

Affiliation:

1. The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney Sydney New South Wales Australia

2. Faculty of Medicine and Health University of New South Wales Sydney New South Wales Australia

3. Sydpath, St Vincent's Pathology Sydney New South Wales Australia

4. Genesis Care Radiation Oncology, St Vincent's Hospital Sydney New South Wales Australia

5. Department of Renal Medicine, Concord Repatriation General Hospital Concord New South Wales Australia

6. Faculty of Medicine and Health the University of Sydney Sydney New South Wales Australia

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18649

Reference7 articles.

1. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

2. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

3. Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis

4. Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study.

5. ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3